
Over 29 pharma firms advance 35+ Treg cell therapies, promising new treatments for autoimmune and transplant diseases.
The Treg cell-based therapies pipeline is robust with more than 29 pharmaceutical companies developing over 35 therapies targeting autoimmune diseases, graft-versus-host disease, and transplant rejection. Key players like Orca Bio, Cellenkos, and Que...


